IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 11, 2025 · 10-Q · 42 days after period end · 0000950170-25-106535
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$16.05M | -$27.73M | -$4.89M | -$16.56M |
| EPS Diluted | -$68.75 | -$0.64 | -$0.14 | -$0.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end
